Open in interactive viewer → charts, metric popovers & call review

Sagicor's 15% ROE Target Just Got a New Adjective

A one-word change in the guidance language, a reserve scare that migrated from the U.S. to Canada, and a passive-funding insight hiding inside a universal life book
SFC.TO · Earnings Call · 2026-11-12

The adjective that ate two quarters

On its own terms, Sagicor's third quarter was the best of 2026: $39 million of core earnings to shareholders, up 10% year-over-year, an annualized core ROE of 15.1%, and new business CSM of $42 million, up 4%. Every operating segment was within $1 million of its expected insurance experience. And yet the first question on the call was not about earnings. It was about a word. “if I look at the 15% target says medium term as opposed to fiscal 2028. Is there a reason behind that change in language?” — Gabriel Dechaine, Analyst · 2026-11-12 That is the kind of language change that shows up in a transcript before it shows up in a model. CEO Andre Mousseau's answer is a partial denial and a partial confession in the same breath: the targets are unchanged, but the 2027 guidance of 14% now begins mid-year because the Caribbean merger will close in Q1 or Q2, and the company does not have "perfect visibility of what goes into core and what doesn't" once closing costs hit. “we just want the 2027 guidance, which remains at 14%, to start in Q2 or Q3 of next year” — Andre Mousseau, CEO · 2026-11-12. Fourteen percent, in other words, now describes roughly three quarters rather than four. The 15% level is defended; the clock behind it has quietly slipped. That is not a downgrade — it is a deferral dressed as housekeeping, and it is the single most important line in the quarter.

The mortality deep dive that surfaced in Canada instead

For a full quarter, investors had been braced for a different event. In August, management promised a forensic review of U.S. legacy life mortality and floated the possibility of reserve strengthening — “we're taking a very hard look at mortality across the board, including for our U.S. business for Q3 and then maybe that we end up strengthening” — Andre Mousseau, Unknown (likely senior executive, possibly CEO or CFO) · 2026-08-13. The mortality keyword spiked accordingly. The deep dive never landed where the market expected. CFO Kathy Jenkins was unambiguous: “we did not identify a basis for a significant change in our U.S. legacy life book” — Kathy Jenkins, CFO · 2026-11-12. The hit came from Canada instead — a $73 million reduction in net CSM, a 12% sequential decline. Management's own decomposition is worth quoting at length because it reveals how much of this is arithmetic rather than bad news:

Approximately 40% of this change was a result of lapse assumption strengthening related to maturing cohorts of term life insurance. The remainder was due to assumption changes and modeling refinements related to components of future profitability of universal life policies.

Kathy Jenkins, CFO · 2026-11-12
Those are the annual actuarial assumption updates doing their annual damage — cohorts written in 2005 and 2006 finally revealing their rollover behavior. But buried in the follow-up is a genuinely unusual structural insight. Asked why the universal life block's future profitability needed re-modelling, Mousseau pointed at the passive-investing tide: “the passive funds are actually 55% of assets instead of 50% because of the concentration effect in the passive funds, and those are lower fee” — Andre Mousseau, CEO · 2026-11-12. A life insurer's UL economics are a fee stream on policyholder assets; when passive funds win the asset-allocation war, the fee base thins out. That is index-fund market share showing up, a decade later, as an actuarial assumption change inside a Canadian insurer. It is the most interesting sentence in the release and it passed almost unnoticed.

Rates cut both ways, and both sides printed

The $23 million net loss to shareholders — against $39 million of core earnings — is the volatility signature Sagicor has been apologizing for since IFRS 17 arrived. Sharply higher Canadian rates across the curve produced a $15 million net loss in Canada alone; U.S. rates did lesser damage. Here the company's idiosyncrasy meets the market's biggest macro theme: this quarter's global keyword set has rising interest rate environments ranked alongside Fed hike chatter, and Sagicor is one of the rare names where that theme operates in opposite directions simultaneously. Higher rates are accretive to annuity gross margins; they are punitive to a bond portfolio marked through the P&L. Last quarter, Darko Mihelic asked directly whether Sagicor should hedge or shorten duration. Mousseau's answer was a manifesto:

we've made the strategic decision for the time being that we're going to optimize the economics for how much book value generation can we get over the next 2, 3, 4 years and beyond rather than shortening up and feeling it a little bit more comfortable.

Andre Mousseau, Unknown (likely senior executive, possibly CEO or CFO) · 2026-08-13
That strategy was tested again this quarter and produced another net loss. Management's defence has now shifted from principle to periodicity: quarterly marks are too granular because balance-sheet assets dwarf net income, and “the Q2 run rate was too low and the Q3 run rate is probably a little bit higher than the true run rate” — Andre Mousseau, CEO · 2026-11-12. Fair — but investors should note that the volatility defence is now a standing item, not a one-off.

Caribbean: optionality, not just cost takeout

Shareholder approval for the Caribbean combination arrived in October. Closing is expected in H1 2027 — possibly April 1, deliberately the first day of a quarter to spare the finance team. About $8 million of noncore transition costs hit Q3, more will follow, and management explicitly declined to size them. The costs related to the Caribbean reorganisation are now a visible line item rather than a talking point, and the real prize is a year or two out, once legacy systems are decommissioned. But listen to how the framing has moved. A quarter ago this was a 14%-to-15% ROE bridge. Now Mousseau calls cost the "positive offshoot" and the main event something else: a single listed entity trading at a premium to book, a public currency for inorganic growth, and the ability to "play offense" after eight years of COVID, IFRS 17 and structural distraction. That is a more ambitious story than the one sold in August, and a harder one to underwrite.

The bull case that never got airtime

U.S. annuities did $247 million of new business production at strong margins, and the AM Best upgrade from A- to A is opening bank distribution channels previously closed. Mousseau put $1.5 billion of production within the "realm of possibility" over three years versus today's ~$1 billion run rate — genuine distribution expansion upside against a production target he conceded sat at the low end of its range. That, plus a 133% LICAT ratio and $7.36 book value per share, is a coherent story. The tension is that the market is being asked to hold a 15% ROE promise that has just been re-dated into "medium term," absorb another year of merger noise, and tolerate mark-to-market losses that management has philosophically chosen not to mitigate. The machine works. What changed this quarter is not the level of the promise — it is the amount of patience required to collect it.